This inventor holds 8 USPTO granted patents and 11 published patent applications, plus 1 CIPO patent and 7 EPO patents. Top assignees: Engmab Sarl, Bristol-Myers Squibb Compnay, Engmab Ag. Active years: 2018-2026.
Company Filing History:
5 out of 5 
1 out of 3,736 
1 out of 1 
Years Active: 2018-2026
Title: The Innovative Contributions of Minh Diem Vu
Introduction
Minh Diem Vu is a prominent inventor based in Wollerau, Switzerland. She has made significant contributions to the field of biomedicine, particularly in the development of bispecific antibodies. With a total of seven patents to her name, her work has the potential to impact the treatment of various diseases.
Latest Patents
Among her latest patents are bispecific antibodies against CD3EPSILON and ROR1. This invention relates to the manufacture and use of these antibodies, which are crucial for targeted therapies. Another notable patent is for a bispecific antibody against BCMA and CD3, along with an immunological drug for combined use in treating multiple myeloma. This invention specifically binds to human B cell maturation antigen (BCMA) and human CD3, showcasing her innovative approach to immunotherapy.
Career Highlights
Minh Diem Vu has worked with notable companies such as Engmab Sàrl and Engmab AG. Her experience in these organizations has allowed her to refine her skills and contribute to groundbreaking research in the field of immunology.
Collaborations
Some of her coworkers include Klaus Strein and Ekkehard Moessner. Their collaboration has likely fostered an environment of innovation and creativity, leading to the development of impactful medical solutions.
Conclusion
Minh Diem Vu's work in the field of bispecific antibodies exemplifies her dedication to advancing medical science. Her patents and collaborations highlight her role as a key innovator in biomedicine.